Over- and Under-Estimating the Value of Screening Mammography

Breast Cancer ManagementVol. 3, No. 5 EditorialOver- and under-estimating the value of screening mammographyMary E CostanzaMary E Costanza*University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA; E-mail Address: mary.costanza@umassmed.eduPublished Online:27 Oct 2014https://doi.org/10.2217/bmt.14.30AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: benefitsreassessmentrisksscreening mammographyReferences1 Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 311(13), 1327–1335 (2014).Medline CASGoogle Scholar2 Welch HG, Passow HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern. Med. 174(3), 448–453 (2014).MedlineGoogle Scholar3 Miller AB, Wall C, Baines CJ et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348, g366 (2014).MedlineGoogle Scholar4 Elmore JG, Kramer BS. Breast cancer screening. Towards informed decisions. JAMA 311(13), 1298–1299 (2014).Medline CASGoogle Scholar5 Marmot MG, Altman DG, Cameron DA et al. The benefits and harms of breast cancer screening: an independent review. Br. J. Cancer 108, 2205–2240 (2013).Medline CASGoogle Scholar6 Duffy SW, Yen AM, Chen TH et al. Long term benefits of breast cancer screening. Breast Cancer Manage. 1, 31–38 (2012).CASGoogle Scholar7 Duffy SW, Chen TH, Smith RA et al. Real and artificial controversies in breast cancer screening. Breast Cancer Manage. 2(6), 519–528 (2013).CASGoogle Scholar8 Costanza ME. Screening mammograms should not be underestimated. JAMA Arch. Int. Med. 172(5), 446 (2012).MedlineGoogle Scholar9 Jorgensen KJ, Gotzsche PC. Overdiagnosis in publically organised mammography screening programmes: systemic review of incidence trends. BMJ 339, b2587 (2009).MedlineGoogle Scholar10 Puliti D, Duffy SW, Miccinesi G et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J. Med. Screen. 19(Suppl. 1), S42–S56 (2012).MedlineGoogle Scholar11 de Gelder R, Heijnsdijk EAM, van Ravesteyn NT et al. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol. Rev. 33, 111–121 (2011).MedlineGoogle Scholar12 Duffy SW, Lynge E, Jonsson H et al. Complexities in the estimation of overdiagnosis in breast cancer screening. Br. J. Cancer 99, 1176–1178 (2008).Medline CASGoogle Scholar13 Hubbard RA, Kerlikowske K, Flowers CI et al. Cumulative probability of false positive recall or biopsy recommendation after 10 years of screening mammography. Ann. Int. Med. 155, 481–492 (2011).MedlineGoogle Scholar14 American Cancer Society. http://www.cancer.org/treatment/understandingyourdiagnosis/examsandtestdescriptions/mammogramsandotherbreastimagingprocedures/mammograms-and-other-breast-imaging-procedures-what-to-expect.Google Scholar15 O'Donoghue CO, Eklund M, Ozanne EM et al. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann. Int. Med. 160, 145–153 (2014).MedlineGoogle Scholar16 Mandelblatt JS, Cronin KA, Bailey S et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann. Int. Med. 151, 738–747 (2009).MedlineGoogle Scholar17 Field LR, Wilson TE, Strawderman M et al. Mammographic screening in women more than 64 years old: a comparison of 1- and 2-year intervals. AJR 170, 961–965 (1998).Medline CASGoogle Scholar18 Michaelson J, Satija S, Moore R et al. Estimates of the sizes at which breast cancers become detectable on mammographic and clinical grounds. J. Womens Imaging 5(1), 3–10 (2003).Google Scholar19 Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353, 1784–1792 (2005).Medline CASGoogle Scholar20 Reis LAG, Eisner MO. Cancer of the female breast. In: SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988-2001, Patient and Tumor Characteristics. Reis LAG, Young JL, Keel GE et al. (Eds). National Cancer Institute, Bethesda, MD, USA, SEER program NIH Pub. No. 07-6215, 101–110 (2007).Google Scholar21 Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconmonics 27(3), 199–209 (2009).MedlineGoogle ScholarFiguresReferencesRelatedDetails Vol. 3, No. 5 STAY CONNECTED Metrics Downloaded 32 times History Published online 27 October 2014 Published in print September 2014 Information© Future Medicine LtdKeywordsbenefitsreassessmentrisksscreening mammographyFinancial & competing interests disclosureSupported in part by the NIH, National Cancer Institute (R01CA 132935). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download